Recombinant Human ITPKA Protein, N-His

Description of Recombinant Human ITPKA Protein, N-His

Introduction

The use of recombinant proteins has revolutionized the field of biotechnology and has paved the way for the development of novel therapeutics and diagnostics. One such recombinant protein that has gained significant attention is the Recombinant Human ITPKA Protein. In this article, we will explore the structure, activity, and application of this protein in detail.

Structure of Recombinant Human ITPKA Protein

The Recombinant Human ITPKA Protein, also known as Inositol-trisphosphate 3-kinase A, is a member of the inositol phosphate kinase family. It is encoded by the ITPKA gene and is composed of 518 amino acids with a molecular weight of approximately 58 kDa. The protein consists of three distinct domains: an N-terminal domain, a central catalytic domain, and a C-terminal domain. The N-terminal domain is responsible for binding to the lipid substrate, while the catalytic domain contains the active site where the phosphorylation of inositol phosphate takes place. The C-terminal domain is involved in protein-protein interactions and is crucial for the regulation of the enzyme’s activity.

Activity of Recombinant Human ITPKA Protein

The main function of the Recombinant Human ITPKA Protein is to phosphorylate inositol 1,4,5-trisphosphate (IP3) to produce inositol 1,3,4,5-tetrakisphosphate (IP4). This reaction is essential for the regulation of intracellular calcium levels, which play a crucial role in various cellular processes such as cell growth, differentiation, and apoptosis. The Recombinant Human ITPKA Protein is a key enzyme in the inositol phosphate signaling pathway and is involved in the regulation of various physiological and pathological processes.

Application of Recombinant Human ITPKA Protein

The Recombinant Human ITPKA Protein has a wide range of applications in both research and clinical settings. One of the major applications of this protein is in the production of recombinant antibodies. The catalytic domain of the protein is used as a fusion partner to produce recombinant antibodies with high specificity and affinity. These antibodies have been used in various diagnostic and therapeutic applications, including cancer treatment.

Another important application of the Recombinant Human ITPKA Protein is in the development of novel therapeutics. The dysregulation of inositol phosphate signaling has been linked to various diseases, including cancer, diabetes, and neurodegenerative disorders. The Recombinant Human ITPKA Protein has been targeted as a potential therapeutic target for these diseases, and several inhibitors have been developed to block its activity. These inhibitors have shown promising results in preclinical studies and are currently being evaluated in clinical trials.

In addition to its role in therapeutics, the Recombinant Human ITPKA Protein has also been used in basic research to study the inositol phosphate signaling pathway. The recombinant protein can be used to investigate the function of the enzyme in different cellular processes and to identify potential drug targets. It has also been used to study the role of inositol phosphate signaling in various diseases, providing valuable insights into disease mechanisms and potential therapeutic interventions.

Conclusion

In summary, the Recombinant Human ITPKA Protein is a crucial enzyme involved in the regulation of intracellular calcium levels and has a wide range of applications in research and medicine. Its unique structure and activity make it a valuable tool for the production of recombinant antibodies and the development of novel therapeutics. As our understanding of the inositol phosphate signaling pathway continues to grow, the potential applications of this protein are likely to expand, making it an important molecule in the field of biotechnology.